Given these findings, the effect of adding finerenone to existing dual therapy with an SGLT2i and a GLP-1 RA in individuals with T2D and CKD warrants real-world observational evaluation The aim of this study was to assess the impact of adding finerenone to existing SGLT2i and GLP-1 RA therapy by examining adjusted percent change in UACR and adjusted changes in eGFR and serum potassium after finerenone initiation. Here, GLP1R is linked to type 2 diabetes mellitus.